Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

DOG1 for the Diagnosis of Gastrointestinal Stromal Tumor (GIST): Comparison Between 2 Different Antibodies

DOG1 for the Diagnosis of Gastrointestinal Stromal Tumor (GIST): Comparison Between 2... RESEARCH ARTICLE DOG1 for the Diagnosis of Gastrointestinal Stromal Tumor (GIST): Comparison Between 2 Different Antibodies Lisandro F. Lopes, MD, PhD,* Robert B. West, MD, PhD,w Livia M. Bacchi, MS,z Matt van de Rijn, MD, PhD,w and Carlos E. Bacchi, MD, PhD* receptor a (PDGFRA) activating mutations]. KIT and Abstract: Gastrointestinal stromal tumor (GIST) is the most PDGFRA encode for similarly named receptors (KIT and common mesenchymal neoplasm of the gastrointestinal tract. PDGFRA) that can be inactivated by tyrosine kinase Discovered on GIST-1 (DOG1) is a recently described protein inhibitors, such as imatinib and sunitinib. On account of expressed in GISTs irrespective of mutation status. The aim of the availability of specific treatment, the accurate diag- 1–8 this study was to investigate the immunohistochemical expres- nosis of GIST is of great importance. KIT immuno- sion of DOG1 using 2 different monoclonal antibodies (DOG1.1 histochemical expression is observed in most GISTs, and the commercially available K9 antibody) in 668 GIST cases whereas other mesenchymal neoplasms that enter in the and to compare the results with the expression of KIT. DOG1 differential diagnosis of GIST are generally negative; 9,10 and KIT expression also were studied in most human normal however, up http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

DOG1 for the Diagnosis of Gastrointestinal Stromal Tumor (GIST): Comparison Between 2 Different Antibodies

Loading next page...
 
/lp/wolters-kluwer-health/dog1-for-the-diagnosis-of-gastrointestinal-stromal-tumor-gist-colon-33Oiswu0tV

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1541-2016

Abstract

RESEARCH ARTICLE DOG1 for the Diagnosis of Gastrointestinal Stromal Tumor (GIST): Comparison Between 2 Different Antibodies Lisandro F. Lopes, MD, PhD,* Robert B. West, MD, PhD,w Livia M. Bacchi, MS,z Matt van de Rijn, MD, PhD,w and Carlos E. Bacchi, MD, PhD* receptor a (PDGFRA) activating mutations]. KIT and Abstract: Gastrointestinal stromal tumor (GIST) is the most PDGFRA encode for similarly named receptors (KIT and common mesenchymal neoplasm of the gastrointestinal tract. PDGFRA) that can be inactivated by tyrosine kinase Discovered on GIST-1 (DOG1) is a recently described protein inhibitors, such as imatinib and sunitinib. On account of expressed in GISTs irrespective of mutation status. The aim of the availability of specific treatment, the accurate diag- 1–8 this study was to investigate the immunohistochemical expres- nosis of GIST is of great importance. KIT immuno- sion of DOG1 using 2 different monoclonal antibodies (DOG1.1 histochemical expression is observed in most GISTs, and the commercially available K9 antibody) in 668 GIST cases whereas other mesenchymal neoplasms that enter in the and to compare the results with the expression of KIT. DOG1 differential diagnosis of GIST are generally negative; 9,10 and KIT expression also were studied in most human normal however, up

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jul 1, 2010

There are no references for this article.